Every third patient had a chronic or relapsed course of ENT diseases, such as chronic tonsillitis, adenoiditis, otitis, sinusitis, etc. Biological treatment was carried out in 217 (58.5%) patients, biological monotherapy in 102 patients (27.5%), and a combination with non-biologic DMARDs in 115 (31.0%) patients The majority of patients received TNF blockers (n = 202, 93.1%); 136 (36.7%) patients received methotrexate. The gene discussed is TNF; the disease is Recurrent tonsillitis.